An Open-label, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO to Explore the Anamnestic Immune Response in Healthy Children Vaccinated 10 Years Ago With a Primary Series (3 Doses) of Either HEXAVAC or INFANRIX HEXA
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2017
Price : $35 *
At a glance
- Drugs Hepatitis B vaccine recombinant (HBvaxPro) (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors sanofi pasteur; sanofi pasteur MSD
- 29 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov.
- 11 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov record.
- 23 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.